Treatment Outcome of Uveitis in Autoimmune Diseases
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03886233 |
Recruitment Status : Unknown
Verified March 2019 by Elham youssif Ahmed Ali, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : March 22, 2019
Last Update Posted : March 22, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Autoimmune Uveitis | Drug: Corticosteroid Series |
Study Type : | Observational |
Estimated Enrollment : | 1 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Treatment Outcome of Uveitis in Autoimmune Diseases |
Estimated Study Start Date : | March 2019 |
Estimated Primary Completion Date : | February 2021 |
Estimated Study Completion Date : | February 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Traditional Treatment for Autoimmune uveitis
Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
|
Drug: Corticosteroid Series
immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
Other Names:
|
Biological Treatment for Autoimmune uveitis
Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
|
- determination the best method for treatment of autoimmune uveitis [ Time Frame: 2 years ]compare the rates of treatment failure in the management of autoimmune uveitis between patients who received steroids, immunosuppressive drugs or biological therapies.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Uveitis with clinical features of autoimmune disease;
Exclusion Criteria:
- Other infectious and non-infectious uveitic etiologies that may mimic the given clinical presentation of autoimmune uveitis;

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03886233
Contact: Elham Y Ahmed, Bachelor | 01144710803 | elhamyoussef06@gmail.com |
Study Chair: | Hasan L Fahmy, Prof. | Assiut University | |
Study Director: | Mohamed G Saleh, lecturer | Assiut University |
Responsible Party: | Elham youssif Ahmed Ali, Assiut, Assiut University |
ClinicalTrials.gov Identifier: | NCT03886233 |
Other Study ID Numbers: |
IRB000188 |
First Posted: | March 22, 2019 Key Record Dates |
Last Update Posted: | March 22, 2019 |
Last Verified: | March 2019 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Uveitis Autoimmune Diseases Uveal Diseases Eye Diseases |
Immune System Diseases Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |